On 13 July 2026, the UK and Switzerland announced the conclusion of negotiations for an enhanced Free Trade Agreement (“FTA”) (see here and here).…
- Switzerland: EU Pharma Package – Tax Implications
- The EU AI Act’s First Harmonised Standard: What’s Next for Medical Device Manufacturers?
- The Next EHDS Implementation Wave: What Pharma and MedTech Need to Do Next
- SRB Is Not a Shortcut to Anonymity: What Recent CNIL and Garante Decisions Mean for Health Data in the EU
- EU Pharma Package: When Will the New Rules Apply?
- The UK-Switzerland FTA and the Internationalisation of Pharmaceutical Exclusivity
- Impact of MFN Pricing on Transactions
- United States: HHS-OIG Issues Unfavorable Advisory Opinion on Physician Royalty Arrangements with Device Company
Recent US efforts to introduce Most Favored Nation (MFN) drug pricing are creating new layers of uncertainty for transactions involving the commercialization of prescription…
United States: HHS-OIG Issues Unfavorable Advisory Opinion on Physician Royalty Arrangements with Device Company
In brief On May 18, 2026, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) released an unfavorable Advisory Opinion…
Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…
On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…
In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…
The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…
As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…
As already well noted on this blog, on 26 April 2023 the European Commission published a set of…









